Shopping Cart 0
Cart Subtotal
AED 0

Otitis Media - Pipeline Review, H1 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020

Details

Otitis Media-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media-Pipeline Review, H1 2019, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).

- The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Otitis Media-Overview

Otitis Media-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Otitis Media-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Otitis Media-Companies Involved in Therapeutics Development

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Novus Therapeutics Inc

Yuhan Corp

Otitis Media-Drug Profiles

(cholesteryl palmitate + colfosceril palmitate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(dexamethasone + piperacillin + tazobactam)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazufloxacin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCL-1440-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal (13-valent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal (23-valent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Otitis Media-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Otitis Media-Dormant Projects

Otitis Media-Product Development Milestones

Featured News & Press Releases

Jan 30, 2019: Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials

Jan 10, 2019: Novus doses first patient in Phase I trial of OP0201

Dec 04, 2018: Novus Therapeutics announces formation of Scientific Advisory Board

Nov 28, 2018: Novus Therapeutics doses first subject in Phase I trial of OP0201

Jun 19, 2018: Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media

Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections

Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Otitis Media, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Otitis Media, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Otitis Media-Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2019

Otitis Media-Pipeline by Madam Therapeutics BV, H1 2019

Otitis Media-Pipeline by Merck & Co Inc, H1 2019

Otitis Media-Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2019

Otitis Media-Pipeline by Novus Therapeutics Inc, H1 2019

Otitis Media-Pipeline by Yuhan Corp, H1 2019

Otitis Media-Dormant Projects, H1 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Otitis Media Therapeutic Products under Development, Key Players in Otitis Media Therapeutics, Otitis Media Pipeline Overview, Otitis Media Pipeline, Otitis Media Pipeline Assessment


Companies

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Novus Therapeutics Inc

Yuhan Corp

Company Profile

Company Profile Title

Otitis Media-Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media-Pipeline Review, H1 2019, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.

Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media-Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).

- The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Otitis Media-Overview

Otitis Media-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Otitis Media-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Otitis Media-Companies Involved in Therapeutics Development

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Novus Therapeutics Inc

Yuhan Corp

Otitis Media-Drug Profiles

(cholesteryl palmitate + colfosceril palmitate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(dexamethasone + piperacillin + tazobactam)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

finafloxacin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazufloxacin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCL-1440-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal (13-valent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pneumococcal (23-valent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Otitis Media-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Otitis Media-Dormant Projects

Otitis Media-Product Development Milestones

Featured News & Press Releases

Jan 30, 2019: Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials

Jan 10, 2019: Novus doses first patient in Phase I trial of OP0201

Dec 04, 2018: Novus Therapeutics announces formation of Scientific Advisory Board

Nov 28, 2018: Novus Therapeutics doses first subject in Phase I trial of OP0201

Jun 19, 2018: Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media

Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra's Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media

Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections

Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Otitis Media, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019


List Of Table

List of Tables

Number of Products under Development for Otitis Media, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Otitis Media-Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2019

Otitis Media-Pipeline by Madam Therapeutics BV, H1 2019

Otitis Media-Pipeline by Merck & Co Inc, H1 2019

Otitis Media-Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2019

Otitis Media-Pipeline by Novus Therapeutics Inc, H1 2019

Otitis Media-Pipeline by Yuhan Corp, H1 2019

Otitis Media-Dormant Projects, H1 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Otitis Media Therapeutic Products under Development, Key Players in Otitis Media Therapeutics, Otitis Media Pipeline Overview, Otitis Media Pipeline, Otitis Media Pipeline Assessment


Companies

Lee's Pharmaceutical Holdings Ltd

Madam Therapeutics BV

Merck & Co Inc

MerLion Pharmaceuticals Pte Ltd

Novus Therapeutics Inc

Yuhan Corp